NeuExcell Therapeutics
Dr. Yin brings with him over twenty years of leadership experience as a top executive and strategist in the pharmaceutical world. From April 2017 to December 2020, he was Head of Novartis Pharmaceuticals, APMA Region (Asia Pacific, Middle East and Africa), and President of Novartis Group (China). He was a member of the Novartis Pharma Executive Committee. He joined Novartis in 2011 as Chairman of Novartis Group (China) and has been instrumental to the success of Novartis Group and all its divisions (including Novartis Pharmaceuticals, Sandoz and Alcon) in China.
Prior to Novartis, Dr. Yin served as President of AstraZeneca China (including Mainland and Hong Kong), and successfully led AstraZeneca China to be the first big pharma to grow into a USD 1 billion business. Before AstraZeneca, he worked at the Boston Consulting Group, focusing on pharmaceutical industry clients in Asia.
Dr. Yin received his bachelor’s degree in Biochemistry from Peking University, MBA from Harvard Business School, and PhD in Biological Science from Stanford University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
NeuExcell Therapeutics
1 followers
NeuExcell is an early stage gene therapy company focusing on neurodegenerative diseases. They have developed a disruptive neural repair technology that utilizes in vivo astrocyte-to-neuron conversion.